Southpoint Capital Advisors LP Sells 69,976 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Southpoint Capital Advisors LP decreased its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 10.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 600,000 shares of the medical research company's stock after selling 69,976 shares during the quarter. Charles River Laboratories International accounts for approximately 2.6% of Southpoint Capital Advisors LP's holdings, making the stock its 21st biggest holding. Southpoint Capital Advisors LP owned approximately 1.17% of Charles River Laboratories International worth $110,760,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Optiver Holding B.V. bought a new stake in shares of Charles River Laboratories International in the 4th quarter worth about $37,000. GeoWealth Management LLC raised its position in Charles River Laboratories International by 311.5% in the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock valued at $46,000 after purchasing an additional 190 shares during the last quarter. Pilgrim Partners Asia Pte Ltd bought a new position in Charles River Laboratories International in the 4th quarter valued at $48,000. Tortoise Investment Management LLC raised its position in Charles River Laboratories International by 77.7% in the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock valued at $49,000 after purchasing an additional 115 shares during the last quarter. Finally, Huntington National Bank raised its position in Charles River Laboratories International by 120.6% in the 4th quarter. Huntington National Bank now owns 300 shares of the medical research company's stock valued at $55,000 after purchasing an additional 164 shares during the last quarter. Institutional investors own 98.91% of the company's stock.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 500 shares of Charles River Laboratories International stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total transaction of $72,705.00. Following the transaction, the executive vice president now owns 19,513 shares in the company, valued at $2,837,385.33. The trade was a 2.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Trading Up 0.9%

Shares of NYSE:CRL traded up $1.16 during midday trading on Friday, hitting $136.76. The company had a trading volume of 775,603 shares, compared to its average volume of 991,241. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $254.15. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The stock has a market cap of $6.72 billion, a price-to-earnings ratio of 911.73, a PEG ratio of 4.54 and a beta of 1.50. The firm has a fifty day simple moving average of $132.05 and a 200 day simple moving average of $163.45.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. During the same period last year, the company earned $2.27 EPS. The firm's revenue was down 2.7% on a year-over-year basis. On average, analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. Robert W. Baird increased their price target on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a research note on Thursday, May 8th. Citigroup raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and raised their price target for the company from $155.00 to $175.00 in a report on Tuesday, March 4th. Redburn Atlantic raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and lowered their price target for the company from $188.00 to $182.00 in a report on Friday. Finally, Morgan Stanley lowered their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $171.85.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).